Resource Links

Here is a list of other resources you may find useful. Some of these organizations also offer newsletters to help keep you informed.

  • Appeal Solutions: Appeal Solutions (www.appealsolutions.com) is a leading provider of services focusing entirely on the resolution of denied or disputed medical insurance claims.
  • Centers for Medicare & Medicaid Services (CMS): The Centers for Medicare & Medicaid Services (www.cms.hhs.gov) is a federal agency within the U.S. Department of Health & Human Services. CMS runs the Medicare and Medicaid programs, two national health care programs that benefit about 75 million Americans.
  • COBRA Insurance: Consolidated Omnibus Budget Reconciliation Act insurance (www.cobrainsurance.net) can provide short-term insurance coverage.
  • HealthInsuranceInfo.net: HealthInsuranceInfo.net (www.healthinsuranceinfo.net) is a consumer guide for getting and keeping health insurance.
  • Maternal and Child Health: The Title V legislation authorized the creation of the Maternal and Child Health programs (https://performance.hrsa.gov/mchb/mchreports), thereby providing the foundation and structure needed to meet the nation's goals for healthy mothers and children.
  • Medicare Newsletter—Medicare Talk: Medicare Talk (www.afmc.org/HTML/publications/consumers/mtalk_pub.aspx) is a quarterly newsletter published by the Arkansas Foundation for Medical Care (AFMC) and is distributed statewide to a senior audience of more than 60,000. This publication is inserted into the popular senior magazine Aging Arkansas. AFMC also maintains an internal mailing list of individual subscribers along with numerous groups and organizations like senior centers, retired teachers, Social Security offices, AARP groups and county health units.
  • NeedyMeds: NeedyMeds (www.needymeds.com) is a place to learn about patient assistance programs and other programs designed to help those who can't afford their medicines. NeedyMeds is not a program but an information source.
  • XPansions: Xpansions (www.xpansions.com) is an innovative patient support program that focuses on helping patients to be compliant and persistent with their XOLAIR® (Omalizumab) for Subcutaneous Use therapy.

XOLAIR (Omalizumab) for Subcutaneous Use Indication

XOLAIR is indicated for adults and adolescents (12 years of age and older) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with ICS. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions.

WARNING

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, patients should be closely observed for an appropriate period of time after XOLAIR administration, and health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Patients should also be informed of the signs and symptoms of anaphylaxis and instructed to seek immediate medical care should symptoms occur (see WARNINGS, and PRECAUTIONS, Information for Patients).

XOLAIR Safety Information

  • XOLAIR should only be administered in a health care setting by health care providers prepared to manage anaphylaxis that can be life- threatening.
  • XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR (see Boxed WARNING). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
  • Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR- treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
  • Patients should be given and instructed to read the Medication Guide before starting treatment and before each subsequent treatment.
  • Patients receiving XOLAIR should be told not to decrease the dose of, or stop taking any other asthma medications unless otherwise instructed by their physician.
  • The adverse reactions most commonly observed among patients treated with XOLAIR in clinical studies included injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.

Please note: This website contains links to a number of other sites that may offer useful information. We suggest visiting those sites directly to obtain information on specific details of coverage, educational and financial support services for XOLAIR® (Omalizumab). Genentech, Inc. and Novartis Pharmaceuticals Corporation are not partners with or affiliated with any company listed. The availability of health insurance coverage and financial assistance varies from company to company, plan to plan and state to state. Genentech, Inc. and Novartis Pharmaceuticals Corporation do not imply or guarantee that a specific health insurance plan or any other company will provide coverage or assistance for XOLAIR. Genentech, Inc. and Novartis Pharmaceuticals Corporation are not responsible for any decisions regarding partial or non-coverage of XOLAIR.

support line